Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 106

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 106
---
 consummation
of the initial business combination, including interest (net of funds withdrawn to pay our taxes, if any), divided by the number of then
issued and outstanding public shares, subject to certain limitations. Our public shareholders will be permitted to redeem their shares
regardless of whether they abstain, vote for, vote against, or vote at all with respect to the proposed business combination. There will
be no redemption rights upon the completion of our initial business combination with respect to our rights. Our sponsor, directors and
officers have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect
to any shares held by them in connection with the completion of our initial business combination.

If a shareholder vote on our initial business
combination is not required by law and we do not decide to hold a shareholder vote for business or other legal reasons, we will offer
to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E under the Exchange Act, and will file tender offer documents with
the SEC prior to completing our initial business combination which contain substantially the same financial and other information about
our initial business combination and the redemption rights as is required under Regulation 14A under the Exchange Act.

Results of Operations

We have neither engaged in any operations nor
generated any revenues to date. Our only activities from May 23, 2024 (inception) through June 30, 2025 were organizational activities,
those necessary to prepare for the Initial Public Offering, described below, and subsequent to the Initial Public Offering, identifying
a target company for an initial business combination. We do not expect to generate any operating revenues until after the completion of
our initial business combination. We generate non-operating income in the form of interest earned on cash and investments held in the
trust account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance),
as well as for due diligence expenses.

For the three months ended June 30, 2025, we had
a net income of $2,288,579, which consists of interest earned on cash and investments held in the trust account of $2,420,498, offset
by general and administrative costs of $131,919.

For the six months ended June 30, 2025, we had
a net income of $3,543,122, which consists of interest earned on cash and investments held in the trust account